Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Children and teenagers between 2 and 18 years old who have a type of blood cancer called B-cell acute lymphoblastic leukaemia (B-ALL) that has come back or stopped responding to treatment, and whose cancer cells carry a marker called CD19
- The cancer must be present in the bone marrow at the time of joining
- The person must be well enough to go through a blood-filtering procedure called apheresis, which collects certain cells from the blood
- A life expectancy of more than 12 weeks
- A general health and ability-to-function score above 50% as measured by standard medical scales used for children and adults (confirm with trial site)
- At least 7 days must have passed since the last chemotherapy treatment and the last use of steroid medications
- The patient and/or their guardian must provide informed consent to participate
- A suitable donor for a stem cell transplant must already be available
Who may not be able to join:
- People who have another active cancer in addition to the B-ALL being studied
- People who have a type of tumour formed by leukaemia cells outside the bone marrow (called a chloroma), signs of leukaemia affecting the brain or spinal cord on an MRI scan, or significant neurological symptoms
- People with any disorder affecting the brain or nervous system
- People with an active condition called graft-versus-host disease (GVHD), where previously transplanted cells are attacking the body
- People who have received radiation therapy within the last 14 days
- People who have previously received treatments that targeted CD19 or CD20 markers on cancer cells
- People who have received donor lymphocyte injections or any other cell-based therapy within the last 30 days
- People with a serious active infection at the time of joining
- People with significant problems affecting the function of major organs such as the heart, liver, or kidneys
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +989124779968
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of patients with overall remission rate (ORR) of complete response (CR) or complete remission with incomplete blood count recovery (CRi); Overall survival; Incidence of cytokine release syndrome: grade 3 and 4; Incidence of Immune effector cell-associated neurotoxicity syndrome (ICANS): grade 3 and 4; Event-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.